3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
UNKNOWN
1
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
104
Multiple Myeloma
66
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Myelodysplastic Syndromes
51
Lymphoma, Non-Hodgkin
51
Leukemia
50
Hodgkin Disease
42
Lymphoma, Mantle-Cell
29
Lymphoma, Large B-Cell, Diffuse
29
Leukemia, Lymphocytic, Chronic, B-Cell
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23
Lymphoma, Follicular
22
Burkitt Lymphoma
22
Breast Neoplasms
22
Recurrence
20
Neoplasms, Plasma Cell
18
Neuroblastoma
17
Hematologic Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
15
Myeloproliferative Disorders
14
Lymphoma, Large-Cell, Immunoblastic
14
Leukemia, Myelomonocytic, Chronic
12
Leukemia, Biphenotypic, Acute
12
Congenital Abnormalities
12
Blast Crisis
10
Anemia, Refractory, with Excess of Blasts
10
Retinoblastoma
9
Central Nervous System Neoplasms
9
Sarcoma
8
Interventions
Carboplatin
88
pembrolizumab
85
Paclitaxel
71
Cyclophosphamide
63
Capecitabine
38
Doxorubicin
37
Taxes
29
130-nm albumin-bound paclitaxel
29
Cisplatin
25
Albumin-Bound Paclitaxel
22
Epirubicin
21
Drug Therapy
21
Docetaxel
20
sacituzumab govitecan
19
olaparib
19
camrelizumab
18
atezolizumab
18
Gemcitabine
17
eribulin
16
durvalumab
16
Bevacizumab
16
Radiotherapy
15
toripalimab
14
Specimen Handling
14
Biopsy
13
Everolimus
12
Magnetic Resonance Spectroscopy
11
apatinib
10
Nivolumab
10
talazoparib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Triple Negative Breast Neoplasms
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05520723
2025-12-04
PRIMED
MedSIR
Phase 2
Completed
50 enrolled